Blog

DEEP RESEARCH · DONG-A ST

DA-5221 Phase 3 Top-line: Best-in-Class Efficacy Signal and Dual-Portfolio Strategy

A rewrite of Dong-A ST’s DA-5221 triple-combination diabetes data by component, trial design, and portfolio strategy.

Date: 2025-11-10 · Personal research rewrite · Original Naver Blog post

You are responsible for your own investment decisions. This material is research, not a recommendation to buy or sell.

0. Bottom line first

DA-5221's 24-week placebo-adjusted HbA1c reduction of -0.77% (p<0.0001) is numerically stronger than comparable triple-combination trials at about -0.66% to -0.72%. Final value depends on 52-week safety durability and commercialization positioning.

ItemContentInvestment meaning
ComponentsEvogliptin + Empagliflozin + MetforminCombines SugarNon with the Jardiance prescription market
Patients174, above target of 162Core patient group for triple therapy
Primary endpoint24-week HbA1c changeTests glucose-lowering efficacy
High-dose result-0.77% vs placebo, p<0.0001Best-in-Class signal
SafetyNo serious adverse drug reaction; mild ADRNeeds 52-week extension confirmation

1. Asset deconstruction: DA5221-B1, B2, and T

Official fact: Trial registration identifies DA5221-B2 as a DPP-4 inhibitor and DA5221-T as an SGLT-2 inhibitor. The source interprets B2 as Dong-A ST's SugarNon (Evogliptin), T as Jardiance's ingredient Empagliflozin, and B1 as first-line Metformin.

DA-5221 single-pill combinationthree mechanisms combined
DA5221-B1Metformin
DA5221-B2Evogliptin / SugarNon
DA5221-TEmpagliflozin / Jardiance
SPCtriple single-pill combination
This is a pivotal add-on study of Empagliflozin in patients inadequately controlled on Metformin + Evogliptin.

2. Trial design and efficacy

  • The study enrolled 174 type 2 diabetes patients inadequately controlled on Metformin + Evogliptin dual therapy.
  • It used a multicenter, double-blind, placebo-controlled, randomized, parallel design.
  • Patients received one of two DA5221-T doses or placebo for 24 weeks on top of existing dual therapy.
  • The primary endpoint was HbA1c change from baseline at 24 weeks, analyzed with MMRM.

3. Dual-portfolio strategy

Dong-A ST already commercialized SugarTree, a dapagliflozin-based triple combination. DA-5221 is not simply a replacement; it is a flanking move into the Jardiance (Empagliflozin) prescription market, described as more than 55% of the SGLT2-inhibitor market.

Commercial

SugarTree

Dapagliflozin-based triple combination.

Development

DA-5221

Empagliflozin-based triple combination targeting the Jardiance prescribing base.

4. Safety and commercialization

Interpretation: No serious adverse drug reactions and mild ADR are positive signals against SGLT2-class prescribing barriers such as urinary and genital infections. The same profile must hold in the 52-week extension to become a strong commercial differentiator.

5. What to verify

  • Whether HbA1c, weight, and safety profiles hold in the 52-week extension.
  • Whether SugarTree and DA-5221 split the SGLT2 ingredient markets instead of cannibalizing each other.
  • Approval, reimbursement, pricing strategy, and prescription switching versus existing DPP-4/SGLT2 combinations.

Sources

Naver original